摘要
目的:观察吉非替尼联合培美曲塞二钠和顺铂对晚期肺腺癌的临床疗效。方法:将98例晚期肺腺癌患者随机分为对照组和研究组,各49例。对照组给予培美曲塞二钠+顺铂方案进行治疗,研究组在对照组基础上加用吉非替尼治疗,对比两组临床疗效、肿瘤标志物水平和不良反应。结果:研究组治疗总有效率高于对照组;两组的肿瘤标志物水平均低于治疗前,且研究组低于对照组;研究组不良反应发生率低于对照组(P<0.05)。结论:吉非替尼联合培美曲塞二钠和顺铂治疗晚期肺腺癌的疗效良好,无明显不良反应,具有一定的临床应用价值。
Objective:To investigate the clinical efficacy of gefitinib combined with pemetrexed disodium and cisplatin in the treatment of advanced lung adenocarcinoma.Methods:Ninety-eight patients with advanced lung adenocarcinoma were randomly divided into a control group and a study group,with 49 cases each.The control group was treated with pemetrexed disodium combined with cisplatin,while the study group was treated with gefitinib besides pemetrexed disodium combined with cisplatin.Clinical efficacy,levels of tumor markers and incidence of adverse events were compared between the two groups.Results:The overall clinical efficacy was higher in the study group than the control group.The levels of tumor markers in both groups were lower after treatment than before and moreover in the study group than the control group.The incidence of adverse events was lower in the study group than the control group(P<0.05).Conclusion:Gefitinib combined with pemetrexed disodium and cisplatin for the treatment of advanced lung adenocarcinoma has good efficacy,no significant adverse effects and a certain clinical application value.
作者
陈辉
崔明良
黄武君
CHEN Hui;CUI Mingliang;HUANG Wujun(Department of Oncology,Balihu General Hospital of the First People’s Hospital of Jiujiang City,Jiujiang 332000,China)
出处
《上海医药》
CAS
2023年第5期19-20,29,共3页
Shanghai Medical & Pharmaceutical Journal
关键词
吉非替尼
培美曲塞二钠
顺铂
晚期肺腺癌
gefitinib
pemetrexed disodium
cisplatin
advanced lung adenocarcinoma
作者简介
陈辉,主治医师。研究方向:肿瘤放化疗。
